Fluorescent Polymer Nanocomposites As Novel Drug-Loading and Targeted Delivery Nanocarriers for Glioma Therapy by Modulating ERBB4

Overview

Journal J Fluoresc

Specialties Biophysics
Chemistry

Date 2024 Dec 18

PMID 39693013

Authors

Jian Li

Hui-Qing Lv

Fei Wu

Xue-En Li

Affiliations

Soon will be listed here.

Abstract

Gliomas are the most common type of tumor in the human central nervous system, characterized by high aggressiveness, elevated mortality, and poor prognosis. Therefore, developing new therapeutic strategies is crucial for improving glioma treatment. Temozolomide (TMZ) is widely used in glioma therapy due to its excellent ability to penetrate the blood-brain barrier. In this study, we synthesized HA-PEG@ICG using hyaluronic acid (HA) and polyethylene glycol (PEG), modified with the fluorescent compound indocyanine green (ICG), and thoroughly characterized the product's structure. Subsequently, compound 1 and TMZ were co-loaded onto this carrier to construct a synergistic drug delivery system (HA-PEG@ICG@1@TMZ). Additionally, we evaluated the inhibitory effects and mechanisms of HA-PEG@ICG@1@TMZ on glioma cell proliferation. Our study lays the foundation for further exploration of TMZ-based therapies for glioma treatment.

References

Li X, Liu M, Zhao J, Ren T, Yan X, Zhang L . Research Progress About Glioma Stem Cells in the Immune Microenvironment of Glioma. Front Pharmacol. 2021; 12:750857. PMC: 8495125. DOI: 10.3389/fphar.2021.750857. View

Wang M, Shen S, Hou F, Yan Y . Pathophysiological roles of integrins in gliomas from the perspective of glioma stem cells. Front Cell Dev Biol. 2022; 10:962481. PMC: 9523240. DOI: 10.3389/fcell.2022.962481. View

Weller M, Wen P, Chang S, Dirven L, Lim M, Monje M . Glioma. Nat Rev Dis Primers. 2024; 10(1):33. DOI: 10.1038/s41572-024-00516-y. View

Xu J, Guo Y, Ning W, Wang X, Li S, Chen Y . Comprehensive Analyses of Glucose Metabolism in Glioma Reveal the Glioma-Promoting Effect of GALM. Front Cell Dev Biol. 2022; 9:717182. PMC: 8811465. DOI: 10.3389/fcell.2021.717182. View

Xu X, Li L, Luo L, Shu L, Si X, Chen Z . Opportunities and challenges of glioma organoids. Cell Commun Signal. 2021; 19(1):102. PMC: 8504127. DOI: 10.1186/s12964-021-00777-0. View

Venkatesh H, Morishita W, Geraghty A, Silverbush D, Gillespie S, Arzt M . Electrical and synaptic integration of glioma into neural circuits. Nature. 2019; 573(7775):539-545. PMC: 7038898. DOI: 10.1038/s41586-019-1563-y. View

Ren Y, Miao C, Tang L, Liu Y, Ni P, Gong Y . Homotypic Cancer Cell Membranes Camouflaged Nanoparticles for Targeting Drug Delivery and Enhanced Chemo-Photothermal Therapy of Glioma. Pharmaceuticals (Basel). 2022; 15(2). PMC: 8879672. DOI: 10.3390/ph15020157. View

Zhang Y, Xiao W, He S, Xia X, Yang W, Yang Z . Lipid-mediated protein corona regulation with increased apolipoprotein A-I recruitment for glioma targeting. J Control Release. 2024; 368:42-51. DOI: 10.1016/j.jconrel.2024.02.020. View

Lai G, Wu H, Yang K, Hu K, Zhou Y, Chen X . Progress of nanoparticle drug delivery system for the treatment of glioma. Front Bioeng Biotechnol. 2024; 12:1403511. PMC: 11196769. DOI: 10.3389/fbioe.2024.1403511. View

10.

Wang R, Wang X, Zhao H, Li N, Li J, Zhang H . Targeted delivery of hybrid nanovesicles for enhanced brain penetration to achieve synergistic therapy of glioma. J Control Release. 2023; 365:331-347. DOI: 10.1016/j.jconrel.2023.11.033. View

11.

Li J, Chai Z, Lu J, Xie C, Ran D, Wang S . ɑβ-targeted liposomal drug delivery system with attenuated immunogenicity enabled by linear pentapeptide for glioma therapy. J Control Release. 2020; 322:542-554. DOI: 10.1016/j.jconrel.2020.04.009. View

12.

Wang F, Zhou Y, Cheng S, Lou J, Zhang X, He Q . Gint4.T-Modified DNA Tetrahedrons Loaded with Doxorubicin Inhibits Glioma Cell Proliferation by Targeting PDGFRβ. Nanoscale Res Lett. 2020; 15(1):150. PMC: 7371771. DOI: 10.1186/s11671-020-03377-y. View

13.

Zhu Y, Liang J, Gao C, Wang A, Xia J, Hong C . Multifunctional ginsenoside Rg3-based liposomes for glioma targeting therapy. J Control Release. 2020; 330:641-657. DOI: 10.1016/j.jconrel.2020.12.036. View

14.

Shueng P, Yu L, Hou H, Chiu H, Lo C . Charge Conversion Polymer-Liposome Complexes to Overcome the Limitations of Cationic Liposomes in Mitochondrial-Targeting Drug Delivery. Int J Mol Sci. 2022; 23(6). PMC: 8954455. DOI: 10.3390/ijms23063080. View

15.

Emamzadeh M, Emamzadeh M, Pasparakis G . Dual Controlled Delivery of Gemcitabine and Cisplatin Using Polymer-Modified Thermosensitive Liposomes for Pancreatic Cancer. ACS Appl Bio Mater. 2022; 2(3):1298-1309. DOI: 10.1021/acsabm.9b00007. View

16.

Mazzotta E, Marazioti A, Mourtas S, Muzzalupo R, Antimisiaris S . Liposomes Coated with Novel Synthetic Bifunctional Chitosan Derivatives as Potential Carriers of Anticancer Drugs. Pharmaceutics. 2024; 16(3). PMC: 10975150. DOI: 10.3390/pharmaceutics16030319. View

17.

Khan T, Waseem R, Zehra Z, Aiman A, Bhardwaj P, Ansari J . Mitochondrial Dysfunction: Pathophysiology and Mitochondria-Targeted Drug Delivery Approaches. Pharmaceutics. 2022; 14(12). PMC: 9785072. DOI: 10.3390/pharmaceutics14122657. View

18.

Singh I, Kumar S, Singh S, Wani M . Overcoming resistance: Chitosan-modified liposomes as targeted drug carriers in the fight against multidrug resistant bacteria-a review. Int J Biol Macromol. 2024; 278(Pt 4):135022. DOI: 10.1016/j.ijbiomac.2024.135022. View

19.

Bigdeli A, MakhmalZadeh B, Feghhi M, SoleimaniBiatiani E . Cationic liposomes as promising vehicles for timolol/brimonidine combination ocular delivery in glaucoma: formulation development and in vitro/in vivo evaluation. Drug Deliv Transl Res. 2022; 13(4):1035-1047. DOI: 10.1007/s13346-022-01266-8. View

20.

Tezcan O, Elshafei A, Benderski K, Rama E, Wagner M, Moeckel D . Effect of Cellular and Microenvironmental Multidrug Resistance on Tumor-Targeted Drug Delivery in Triple-Negative Breast cancer. J Control Release. 2023; 354:784-793. PMC: 7614501. DOI: 10.1016/j.jconrel.2022.12.056. View